Literature DB >> 433966

Bacteremia due to gram-positive cocci in patients with neoplastic disease.

L J Kilton, B E Fossieck, M H Cohen, R H Parker.   

Abstract

Entities:  

Mesh:

Year:  1979        PMID: 433966     DOI: 10.1016/0002-9343(79)91169-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  7 in total

1.  Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.

Authors:  M Hidalgo; J Hornedo; C Lumbreras; J M Trigo; C Gómez; S Perea; A Ruiz; R Hitt; H Cortés-Funes
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Fulminant group A streptococcal infections. Report of two cases.

Authors:  R D Christen; R Moser; P Schlup; K A Neftel
Journal:  Klin Wochenschr       Date:  1990-04-17

Review 3.  [A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside].

Authors:  P Dejace; J Klastersky
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.

Authors:  G Bucaneve; F Menichetti; A Del Favero
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

5.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 6.  Recovery of uncommon bacteria from blood: association with neoplastic disease.

Authors:  J L Beebe; E W Koneman
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Comparative in vitro study of teichomycin A2.

Authors:  V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.